Ocrelizumab Alters Cytotoxic Lymphocyte Function While Reducing EBV-Specific CD8⁺ T-Cell Proliferation in Patients With Multiple Sclerosis.

We noticed a slight reduction in proliferation upon EBV and CMV antigenic challenge after ocrelizumab administration also when we analyzed NK-lymphocyte proliferation; however, these differences did not reach statistical significance ( Figure 4B ).

also in 111,027 other papers